zbh-8k_20210803.htm

0001564590-21-039937.txt : 20210803 0001564590-21-039937.hdr.sgml : 20210803 20210803064548 ACCESSION NUMBER: 0001564590-21-039937 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210803 DATE AS OF CHANGE: 20210803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZIMMER BIOMET HOLDINGS, INC. CENTRAL INDEX KEY: 0001136869 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 134151777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16407 FILM NUMBER: 211137894 BUSINESS ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 BUSINESS PHONE: 5742676131 MAIL ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 FORMER COMPANY: FORMER CONFORMED NAME: ZIMMER HOLDINGS INC DATE OF NAME CHANGE: 20010315 8-K 1 zbh-8k_20210803.htm 8-K zbh-8k_20210803.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2021

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-16407	13-4151777
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 267-6131

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	ZBH	New York Stock Exchange
1.414% Notes due 2022	ZBH 22A	New York Stock Exchange
2.425% Notes due 2026 1.164% Notes due 2027	ZBH 26 ZBH 27	New York Stock Exchange New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 2.02Results of Operations and Financial Condition.

On August 3, 2021, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2021. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

EXHIBIT INDEX
Exhibit No.		Description
99.1		Press release dated August 3, 2021
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 3, 2021

	ZIMMER BIOMET HOLDINGS, INC.

	By:	/s/ Chad F. Phipps
	Name:	Chad F. Phipps
	Title:	Senior Vice President, General Counsel and Secretary

EX-99.1 2 zbh-ex991_6.htm EX-99.1 zbh-ex991_6.htm

345 E. Main St.
Warsaw, IN 46580
www.zimmerbiomet.com	Exhibit 99.1

Media	Investors
Meredith Weissman	Keri Mattox
(703) 346-3127	(215) 275-2431
meredith.weissman@zimmerbiomet.com	keri.mattox@zimmerbiomet.com

	Ezgi Yagci
	(617) 549-2443
	ezgi.yagci@zimmerbiomet.com

Zimmer Biomet Announces Second Quarter 2021 Financial Results

•

Second quarter net sales of $2.027 billion increased 65.3%, 60.7% on a constant currency¹ basis

•

Second quarter diluted earnings per share were $0.67; adjusted¹ diluted earnings per share were $1.90

•

Company updates 2021 financial guidance, narrowing range for full year outlook

(WARSAW, IN) August 3, 2021 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2021. The Company reported second quarter net sales of $2.027 billion, an increase of 65.3% over the prior year period, and an increase of 60.7% on a constant currency basis. Second quarter 2021 net sales increased 1.9% when compared to the pre-pandemic second quarter 2019, and were flat on a constant currency basis. Net earnings for the second quarter of 2021 were $141.9 million, or $400.5 million on an adjusted basis.

Diluted earnings per share were $0.67 for the second quarter. Adjusted diluted earnings per share were $1.90 for the second quarter.

¹	Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release.

Page 1 of 27

“Our performance in the second quarter improved meaningfully from the first quarter 2021 across all regions and product categories as recovery from the global pandemic continued to take hold. While we anticipate some ongoing COVID-19 pressure, we expect continued improvement in procedure volume recovery through the second half of 2021," said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet. "Against this backdrop, Zimmer Biomet has continued to execute, investing in our business, expanding our portfolio and developing and launching innovative products designed to improve mobility and health. This execution enables ZB to build and deliver value for our customers and shareholders and to move our mission forward for the patients we ultimately serve."

Please see the attached schedules accompanying this press release for additional details on performance in the quarter, including sales by Zimmer Biomet’s three geographies and five product categories.

Recent Highlights

Aligned with the ongoing transformation of Zimmer Biomet’s business, key recent highlights include:

•	Publication of the Zimmer Biomet Sustainability Report, aligned with Sustainability Accounting Standards Board (SASB) standards.

•

Receipt of key awards for Zimmer Biomet’s portfolio including the ROSA Knee system for Best Technology Solution in Orthopedics by the Medtech Breakthrough Awards and Orthopaedic Product Innovation of the Year by the Healthcare Asia Medtech Awards. The Tether^TMVertebral Body Tethering System, a first-in-class treatment for children with scoliosis, was also Silver Winner in the 2021 Edison Best New Product Awards in the Advanced Surgical Instruments category.

•	Key additions to the Zimmer Biomet Leadership Team, including the appointment of Wilfred van Zuilen as President of Europe, Middle East and Africa (EMEA) and Nitin Goyal, M.D. to the newly created role of Chief Science, Technology and Innovation Officer.

Geographic and Product Category Sales

The following sales tables provide results by geography and product category for the three and six-month periods ended June 30, 2021, as well as the percentage change compared to the prior year period, on both a reported basis and a constant currency basis.

Page 2 of 27

NET SALES - THREE MONTHS ENDED JUNE 30, 2021
(in millions, unaudited)


						Constant
	Net					Currency
	Sales		% Change			% Change
Geographic Results
Americas	$	1,239.6		69.0	%		68.3	%
EMEA		429.8		96.4			80.5
Asia Pacific		357.5		30.6			24.4
Total	$	2,026.9		65.3	%		60.7	%
Product Categories
Knees
Americas	$	400.3		81.4	%		80.6	%
EMEA		148.6		127.2			109.6
Asia Pacific		116.7		31.2			23.8
Total		665.6		77.5			72.2
Hips
Americas		258.1		51.3			50.4
EMEA		122.5		72.8			59.0
Asia Pacific		94.0		6.6			3.9
Total		474.6		44.0			39.9
S.E.T. *		462.1		57.9			53.0
Dental & Spine		263.5		73.1			69.4
Other		161.1		110.9			105.9
Total	$	2,026.9		65.3	%		60.7	%


* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic

Page 3 of 27

NET SALES - SIX MONTHS ENDED JUNE 30, 2021
(in millions, unaudited)


						Constant
	Net					Currency
	Sales		% Change			% Change
Geographic Results
Americas	$	2,354.6		28.3	%		27.9	%
EMEA		814.0		32.0			21.9
Asia Pacific		705.7		26.4			19.9
Total	$	3,874.3		28.7	%		25.2	%
Product Categories
Knees
Americas	$	759.1		26.8	%		26.3	%
EMEA		279.9		28.4			19.0
Asia Pacific		240.9		29.0			21.0
Total		1,279.9		27.5			23.7
Hips
Americas		493.3		22.4			21.9
EMEA		230.2		26.3			17.1
Asia Pacific		198.1		12.0			7.6
Total		921.6		20.9			17.4
S.E.T. *		879.7		30.6			27.1
Dental & Spine		509.5		37.1			34.1
Other		283.6		42.9			39.2
Total	$	3,874.3		28.7	%		25.2	%


* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic

Financial Guidance

The Company is updating its full-year 2021 financial guidance to narrow its previous projected ranges for revenue growth and adjusted diluted EPS:

Projected Year Ending December 31, 2021
	Previous Guidance	Updated Guidance
2021 reported revenue growth	14.0% - 17.0%	14.5% - 16.5%
Foreign Currency Exchange Impact	1.5%	1.5%
Adjusted Operating Profit Margin⁽¹⁾	26.5% - 27.5%	26.5% - 27.0%
Adjusted Tax Rate⁽¹⁾	16.0% - 16.5%	16.0% - 16.5%
Adjusted Diluted EPS⁽¹⁾	$7.60 - $8.00	$7.65 - $7.95

Page 4 of 27

⁽¹⁾	These measures are non-GAAP financial measures for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures.”

Conference Call

The Company will conduct its second quarter investor conference call today, August 3, 2021, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be archived for replay following the conference call.

About the Company

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the “Investor Relations” section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website or any other website referenced herein is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures

This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-

Page 5 of 27

GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Sales change information for the three and six-month periods ended June 30, 2021 is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.

Net earnings and diluted earnings per share for the three and six-month periods ended June 30, 2021 are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted earnings and adjusted diluted earnings per share exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.

Free cash flow is an additional non-GAAP measure that is presented in this press release. Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts. These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation.

Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures. In addition, constant currency sales changes, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs.

Page 6 of 27

Forward-Looking Non-GAAP Financial Measures

This press release also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2021. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to initial compliance with the European Union Medical Device Regulation; restructuring and other cost reduction initiatives; quality remediation; acquisition, integration, divestiture and related; and certain legal and tax matters. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding sales and earnings guidance, the impact of the COVID-19 pandemic on our business, including any continued recovery, and any statements about our forecasts, expectations, plans, intentions, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: the effects of the COVID-19 global pandemic and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective surgical procedures and our ability to collect accounts receivable; the failure of vaccine rollouts and other strategies to mitigate or reverse the impacts of the COVID-19 pandemic; the failure of elective surgical procedures to recover at the levels or on the timeline anticipated; the risks and uncertainties related to our ability to successfully execute our restructuring plans; our ability to attract, retain and develop the highly skilled employees we need to support our business; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management's attention

Page 7 of 27

from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; the risks and uncertainties associated with the proposed spin-off of our Spine and Dental businesses, including, without limitation, the significant expenses, time and efforts related to implementing such transaction, the ability to complete the transaction on our expected timeline or at all, the tax-free nature of the transaction, possible disruptions in our relationships with customers, suppliers and other business partners, and the possibility that the anticipated benefits and synergies of the transaction, strategic and competitive advantages of each company, and future growth and other opportunities for each company will not be realized within the expected time periods or at all; the success of our quality and operational excellence initiatives, including ongoing quality remediation efforts at our Warsaw North Campus facility; the ability to remediate matters identified in inspectional observations or warning letters issued by the U.S. Food and Drug Administration (FDA), while continuing to satisfy the demand for our products; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; the ability to retain the independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the FDA and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the outcome of government investigations; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors and cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, including the volume-based procurement process in China; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended

Page 8 of 27

December 31, 2020, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.

###

Page 9 of 27


ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, except per share amounts, unaudited)

	2021			2020
Net Sales	$	2,026.9		$	1,226.1
Cost of products sold, excluding intangible asset amortization		581.6			424.5
Intangible asset amortization		154.6			147.7
Research and development		180.5			87.7
Selling, general and administrative		817.4			665.0
Goodwill and intangible asset impairment		16.3			33.0
Restructuring and other cost reduction initiatives		19.6			28.0
Quality remediation		11.0			9.7
Acquisition, integration, divestiture and related		25.4			2.2
Operating expenses		1,806.4			1,397.8
Operating Profit (Loss)		220.5			(171.7	)
Other income, net		8.1			3.8
Interest expense, net		(54.7	)		(54.0	)
Earnings (loss) before income taxes		173.9			(221.9	)
Provision (benefit) for income taxes		31.4			(13.7	)
Net Earnings (Loss)		142.5			(208.2	)
Less: Net earnings (loss) attributable to noncontrolling interest		0.6			(1.6	)
Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.	$	141.9		$	(206.6	)
Earnings (Loss) Per Common Share
Basic	$	0.68		$	(1.00	)
Diluted	$	0.67		$	(1.00	)
Weighted Average Common Shares Outstanding
Basic		208.6			206.8
Diluted		210.7			206.8

Page 10 of 27


ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, except per share amounts, unaudited)

	2021			2020
Net Sales	$	3,874.3		$	3,009.9
Cost of products sold, excluding intangible asset amortization		1,098.0			911.6
Intangible asset amortization		310.1			295.3
Research and development		274.9			186.1
Selling, general and administrative		1,587.5			1,493.9
Goodwill and intangible asset impairment		16.3			645.0
Restructuring and other cost reduction initiatives		41.4			73.0
Quality remediation		21.2			26.1
Acquisition, integration, divestiture and related		38.8			6.6
Operating expenses		3,388.2			3,637.6
Operating Profit (Loss)		486.1			(627.7	)
Other income, net		15.4			6.8
Interest expense, net		(107.0	)		(104.9	)
Earnings (loss) before income taxes		394.5			(725.8	)
Provision (benefit) for income taxes		54.3			(8.5	)
Net Earnings (Loss)		340.2			(717.3	)
Less: Net earnings (loss) attributable to noncontrolling interest		0.2			(2.2	)
Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.	$	340.0		$	(715.1	)
Earnings (Loss) Per Common Share
Basic	$	1.63		$	(3.46	)
Diluted	$	1.62		$	(3.46	)
Weighted Average Common Shares Outstanding
Basic		208.3			206.6
Diluted		210.4			206.6

Page 11 of 27

ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, unaudited)

	June 30,		December 31,
	2021		2020
Assets
Cash and cash equivalents	$	1,042.4	$	802.1
Receivables, net		1,420.4		1,452.7
Inventories		2,533.0		2,450.7
Other current assets		361.0		377.8
Total current assets		5,356.8		5,083.3
Property, plant and equipment, net		2,005.2		2,047.7
Goodwill		9,247.6		9,261.8
Intangible assets, net		6,642.7		7,055.5
Other assets		970.9		969.4
Total Assets	$	24,223.2	$	24,417.7
Liabilities and Stockholders' Equity
Current liabilities	$	1,878.5	$	2,056.9
Current portion of long-term debt		1,050.0		500.0
Other long-term liabilities		1,908.9		2,034.9
Long-term debt		6,802.5		7,626.5
Stockholders' equity		12,583.3		12,199.4
Total Liabilities and Stockholders' Equity	$	24,223.2	$	24,417.7

Page 12 of 27

ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)

	2021			2020
Cash flows provided by (used in) operating activities
Net earnings (loss)	$	340.2		$	(717.3	)
Depreciation and amortization		535.2			508.7
Share-based compensation		46.4			38.3
Goodwill and intangible asset impairment		16.3			645.0
Changes in operating assets and liabilities, net of acquired assets and liabilities
Income taxes		(37.3	)		(46.1	)
Receivables		5.3			272.7
Inventories		(94.4	)		(122.6	)
Accounts payable and accrued expenses		(56.3	)		(233.9	)
Other assets and liabilities		(55.0	)		53.3
Net cash provided by operating activities		700.4			398.1
Cash flows provided by (used in) investing activities
Additions to instruments		(150.5	)		(159.3	)
Additions to other property, plant and equipment		(54.7	)		(59.2	)
Net investment hedge settlements		(9.6	)		26.8
Investments in other assets		(17.4	)		(14.8	)
Net cash used in investing activities		(232.2	)		(206.5	)
Cash flows provided by (used in) financing activities
Proceeds from senior notes		-			1,497.1
Redemption of senior notes		(200.0	)		(1,500.0	)
Dividends paid to stockholders		(99.8	)		(99.1	)
Proceeds from employee stock compensation plans		91.5			61.7
Net cash flows from unremitted collections from factoring programs		-			(19.6	)
Business combination contingent consideration payments		(6.5	)		(7.5	)
Debt issuance costs		-			(19.4	)
Other financing activities		(9.3	)		(6.1	)
Net cash used in financing activities		(224.1	)		(92.9	)
Effect of exchange rates on cash and cash equivalents		(3.8	)		(3.2	)
Increase in cash and cash equivalents		240.3			95.5
Cash and cash equivalents, beginning of period		802.1			617.9
Cash and cash equivalents, end of period	$	1,042.4		$	713.4

Page 13 of 27

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY GEOGRAPHY
FOR THE THREE MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)

	Three Months Ended June 30,
	2021		2020		% Inc			Volume / Mix			Price				Foreign Exchange
Americas	$	1,239.6	$	733.7		69.0	%		70.0	%		(1.7	)	%		0.7	%
EMEA		429.8		218.7		96.4			80.5			-				15.9
Asia Pacific		357.5		273.7		30.6			26.3			(1.9	)			6.2
Total	$	2,026.9	$	1,226.1		65.3	%		62.2	%		(1.5	)	%		4.6	%

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY PRODUCT CATEGORY
FOR THE THREE MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)

	Three Months Ended June 30,
	2021		2020		% Inc			Volume / Mix			Price				Foreign Exchange
Knees	$	665.6	$	375.0		77.5	%		74.3	%		(2.1	)	%		5.3	%
Hips		474.6		329.7		44.0			42.4			(2.5	)			4.1
S.E.T.		462.1		292.7		57.9			52.3			0.7				4.9
Dental & Spine		263.5		152.3		73.1			70.3			(0.9	)			3.7
Other		161.1		76.4		110.9			109.3			(3.4	)			5.0
Total	$	2,026.9	$	1,226.1		65.3	%		62.2	%		(1.5	)	%		4.6	%

Page 14 of 27

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY GEOGRAPHY
FOR THE SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)

	Six Months Ended June 30,
	2021		2020		% Inc			Volume / Mix			Price				Foreign Exchange
Americas	$	2,354.6	$	1,835.0		28.3	%		30.0	%		(2.1	)	%		0.4	%
EMEA		814.0		616.8		32.0			22.1			(0.2	)			10.1
Asia Pacific		705.7		558.1		26.4			21.3			(1.4	)			6.5
Total	$	3,874.3	$	3,009.9		28.7	%		26.8	%		(1.6	)	%		3.5	%

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY PRODUCT CATEGORY
FOR THE SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)

	Six Months Ended June 30,
	2021		2020		% Inc			Volume / Mix			Price				Foreign Exchange
Knees	$	1,279.9	$	1,003.7		27.5	%		25.9	%		(2.2	)	%		3.8	%
Hips		921.6		762.3		20.9			20.0			(2.6	)			3.5
S.E.T.		879.7		673.6		30.6			26.8			0.3				3.5
Dental & Spine		509.5		371.8		37.1			35.1			(1.0	)			3.0
Other		283.6		198.5		42.9			41.1			(1.9	)			3.7
Total	$	3,874.3	$	3,009.9		28.7	%		26.8	%		(1.6	)	%		3.5	%

Page 15 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED NET SALES % CHANGE TO
CONSTANT CURRENCY % CHANGE
(unaudited)


	For the Three Months Ended
	June 30, 2021
				Foreign			Constant
				Exchange			Currency
	% Change			Impact			% Change
Geographic Results
Americas		69.0	%		0.7	%		68.3	%
EMEA		96.4			15.9			80.5
Asia Pacific		30.6			6.2			24.4
Total		65.3	%		4.6	%		60.7	%
Product Categories
Knees
Americas		81.4	%		0.8	%		80.6	%
EMEA		127.2			17.6			109.6
Asia Pacific		31.2			7.4			23.8
Total		77.5			5.3			72.2
Hips
Americas		51.3			0.9			50.4
EMEA		72.8			13.8			59.0
Asia Pacific		6.6			2.7			3.9
Total		44.0			4.1			39.9
S.E.T		57.9			4.9			53.0
Dental & Spine		73.1			3.7			69.4
Other		110.9			5.0			105.9
Total		65.3	%		4.6	%		60.7	%

Page 16 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED NET SALES % CHANGE TO
CONSTANT CURRENCY % CHANGE
(unaudited)


	For the Six Months Ended
	June 30, 2021
				Foreign			Constant
				Exchange			Currency
	% Change			Impact			% Change
Geographic Results
Americas		28.3	%		0.4	%		27.9	%
EMEA		32.0			10.1			21.9
Asia Pacific		26.4			6.5			19.9
Total		28.7	%		3.5	%		25.2	%
Product Categories
Knees
Americas		26.8	%		0.5	%		26.3	%
EMEA		28.4			9.4			19.0
Asia Pacific		29.0			8.0			21.0
Total		27.5			3.8			23.7
Hips
Americas		22.4			0.5			21.9
EMEA		26.3			9.2			17.1
Asia Pacific		12.0			4.4			7.6
Total		20.9			3.5			17.4
S.E.T		30.6			3.5			27.1
Dental, Spine & CMFT		37.1			3.0			34.1
Other		42.9			3.7			39.2
Total		28.7	%		3.5	%		25.2	%

Page 17 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED NET SALES % CHANGE TO
CONSTANT CURRENCY % CHANGE
(unaudited)


	For the Three Months Ended
	June 30,
									Foreign			Constant
	Net Sales								Exchange			Currency
	2021		2019		% Change				Impact			% Change
Geographic Results
Americas	$	1,239.6	$	1,214.3		2.1		%		0.2	%		1.9		%
EMEA		429.8		438.0		(1.9	)			5.4			(7.3	)
Asia Pacific		357.5		336.3		6.3				3.5			2.8
Total	$	2,026.9	$	1,988.6		1.9		%		1.9	%		-		%
Product Categories
Knees	$	665.6	$	696.7		(4.5	)			1.8			(6.3	)
Hips		474.6		478.5		(0.8	)			2.0			(2.8	)
S.E.T		462.1		408.7		13.1				2.3			10.8
Dental & Spine		263.5		257.6		2.3				1.5			0.8
Other		161.1		147.1		9.5				2.0			7.5
Total	$	2,026.9	$	1,988.6		1.9		%		1.9	%		-		%

Page 18 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS
FOR THE THREE MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, except per share amounts, unaudited)


FOR THE THREE MONTHS ENDED JUNE 30, 2021
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Goodwill and intangible asset impairment			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration, divestiture and related			Other income, net			Provision (benefit) for income taxes			Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.			Diluted earnings (loss) per common share
As Reported	$	581.6		$	154.6		$	180.5		$	817.4		$	16.3		$	19.6		$	11.0		$	25.4		$	8.1		$	31.4		$	141.9		$	0.67
Inventory and manufacturing-related charges⁽¹⁾		(7.9	)		-			-			-			-			-			-			-			-			4.6			3.3			0.02
Intangible asset amortization⁽²⁾		-			(154.6	)		-			-			-			-			-			-			-			31.4			123.2			0.58
Goodwill and intangible asset impairment⁽³⁾		-			-			-			-			(16.3	)		-			-			-			-			2.1			14.2			0.07
Restructuring and other cost reduction initiatives⁽⁴⁾		(0.1	)		-			-			-			-			(19.6	)		-			-			-			4.4			15.3			0.07
Quality remediation⁽⁵⁾		-			-			-			-			-			-			(11.0	)		-			-			2.5			8.5			0.04
Acquisition, integration, divestiture and related⁽⁶⁾		-			-			-			-			-			-			-			(25.4	)		-			5.3			20.1			0.10
Litigation⁽⁷⁾		-			-			-			(3.6	)		-			-			-			-			-			0.4			3.2			0.02
European Union Medical Device Regulation⁽⁸⁾		-			-			(10.6	)		-			-			-			-			-			-			2.4			8.2			0.04
Certain R&D agreements⁽⁹⁾		-			-			(65.0	)		-			-			-			-			-			-			14.6			50.4			0.24
Other charges⁽¹⁰⁾		-			-			-			4.5			-			-			-			-			(3.0	)		(2.1	)		(5.4	)		(0.03	)
Swiss tax reform⁽¹¹⁾		-			-			-			-			-			-			-			-			-			(15.4	)		15.4			0.07
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			-			-			(2.2	)		2.2			0.01
As Adjusted	$	573.6		$	-		$	104.9		$	818.3		$	-		$	-		$	-		$	-		$	5.1		$	79.4		$	400.5		$	1.90

FOR THE THREE MONTHS ENDED JUNE 30, 2020
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Goodwill and intangible asset impairment			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration, divestiture and related			Other income, net			Provision (benefit) for income taxes			Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.			Diluted earnings (loss) per common share
As Reported	$	424.5		$	147.7		$	87.7		$	665.0		$	33.0		$	28.0		$	9.7		$	2.2		$	3.8		$	(13.7	)	$	(206.6	)	$	(1.00	)
Inventory and manufacturing-related charges⁽¹⁾		(1.4	)		-			-			-			-			-			-			-			-			3.7			(2.3	)		(0.01	)
Intangible asset amortization⁽²⁾		-			(147.7	)		-			-			-			-			-			-			-			8.1			139.6			0.68
Goodwill and intangible asset impairment⁽³⁾		-			-			-			-			(33.0	)		-			-			-			-			5.7			27.3			0.13
Restructuring and other cost reduction initiatives⁽⁴⁾		-			-			-			-			-			(28.0	)		-			-			-			0.8			27.2			0.13
Quality remediation⁽⁵⁾		(0.2	)		-			-			-			-			-			(9.7	)		-			-			0.6			9.3			0.04
Acquisition, integration, divestiture and related⁽⁶⁾		-			-			-			-			-			-			-			(2.2	)		-			0.1			2.1			0.01
Litigation⁽⁷⁾		-			-			-			(1.3	)		-			-			-			-			-			(6.1	)		7.4			0.04
European Union Medical Device Regulation⁽⁸⁾		-			-			(6.1	)		-			-			-			-			-			-			(0.1	)		6.2			0.03
Other charges⁽¹⁰⁾		-			-			-			(11.9	)		-			-			-			-			(4.6	)		10.7			(3.4	)		(0.02	)
Swiss tax reform⁽¹¹⁾		-			-			-			-			-			-			-			-			-			0.7			(0.7	)		-
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			-			-			(4.1	)		4.1			0.02
Effect of dilutive shares assuming net earnings⁽¹³⁾		-			-			-			-			-			-			-			-			-			-			-			-
As Adjusted	$	422.9		$	-		$	81.6		$	651.8		$	-		$	-		$	-		$	-		$	(0.8	)	$	6.4		$	10.2		$	0.05

Page 19 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, except per share amounts, unaudited)

FOR THE SIX MONTHS ENDED JUNE 30, 2021
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Goodwill and intangible asset impairment			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration, divestiture and related			Other income, net			Provision (benefit) for income taxes			Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.			Diluted earnings (loss) per common share
As Reported	$	1,098.0		$	310.1		$	274.9		$	1,587.5		$	16.3		$	41.4		$	21.2		$	38.8		$	15.4		$	54.3		$	340.0		$	1.62
Inventory and manufacturing-related charges⁽¹⁾		(2.0	)		-			-			-			-			-			-			-			-			10.5			(8.5	)		(0.04	)
Intangible asset amortization⁽²⁾		-			(310.1	)		-			-			-			-			-			-			-			61.2			248.9			1.18
Goodwill and intangible asset impairment⁽³⁾		-			-			-			-			(16.3	)		-			-			-			-			2.1			14.2			0.07
Restructuring and other cost reduction initiatives⁽⁴⁾		(0.2	)		-			-			-			-			(41.4	)		-			-			-			9.3			32.3			0.15
Quality remediation⁽⁵⁾		-			-			-			-			-			-			(21.2	)		-			-			4.7			16.5			0.08
Acquisition, integration, divestiture and related⁽⁶⁾		-			-			-			-			-			-			-			(38.8	)		-			8.3			30.5			0.14
Litigation⁽⁷⁾		-			-			-			(9.7	)		-			-			-			-			-			0.9			8.8			0.04
European Union Medical Device Regulation⁽⁸⁾		-			-			(17.5	)		-			-			-			-			-			-			3.8			13.7			0.07
Certain R&D agreements⁽⁹⁾		-			-			(65.0	)		-			-			-			-			-			-			14.6			50.4			0.24
Other charges⁽¹⁰⁾		-			-			-			1.9			-			-			-			-			(7.1	)		(2.8	)		(6.2	)		(0.03	)
Swiss tax reform⁽¹¹⁾		-			-			-			-			-			-			-			-			-			(18.8	)		18.8			0.09
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			-			-			(0.2	)		0.2			-
As Adjusted	$	1,095.8		$	-		$	192.4		$	1,579.7		$	-		$	-		$	-		$	-		$	8.3		$	147.9		$	759.6		$	3.61

FOR THE SIX MONTHS ENDED JUNE 30, 2020
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Goodwill and intangible asset impairment			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration, divestiture and related			Other income, net			Provision (benefit) for income taxes			Net Earnings (Loss) of Zimmer Biomet Holdings, Inc.			Diluted earnings (loss) per common share
As Reported	$	911.6		$	295.3		$	186.1		$	1,493.9		$	645.0		$	73.0		$	26.1		$	6.6		$	6.8		$	(8.5	)	$	(715.1	)	$	(3.46	)
Inventory and manufacturing-related charges⁽¹⁾		(2.0	)		-			-			-			-			-			-			-			-			5.9			(3.9	)		(0.02	)
Intangible asset amortization⁽²⁾		-			(295.3	)		-			-			-			-			-			-			-			38.2			257.1			1.24
Goodwill and intangible asset impairment⁽³⁾		-			-			-			-			(645.0	)		-			-			-			-			5.7			639.3			3.09
Restructuring and other cost reduction initiatives⁽⁴⁾		-			-			-			-			-			(73.0	)		-			-			-			12.2			60.8			0.29
Quality remediation⁽⁵⁾		0.3			-						-			-			-			(26.1	)		-			-			4.1			21.7			0.11
Acquisition, integration, divestiture and related⁽⁶⁾		-			-			-			-			-			-			-			(6.6	)		-			1.0			5.6			0.03
Litigation⁽⁷⁾		-			-			-			(81.1	)		-			-			-			-			-			11.9			69.2			0.34
European Union Medical Device Regulation⁽⁸⁾		-			-			(17.1	)		-			-			-			-			-			-			2.1			15.0			0.07
Other charges⁽¹⁰⁾		-			-			-			(17.8	)		-			-			-			-			(3.9	)		12.6			1.3			0.01
Swiss tax reform⁽¹¹⁾		-			-			-			-			-			-			-			-			-			(16.2	)		16.2			0.08
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			-			-			3.1			(3.1	)		(0.02	)
Effect of dilutive shares assuming net earnings⁽¹³⁾		-			-			-			-			-			-			-			-			-			-			-			(0.01	)
As Adjusted	$	909.9		$	-		$	169.0		$	1,395.0		$	-		$	-		$	-		$	-		$	2.9		$	72.1		$	364.1		$	1.75

Page 20 of 27

⁽¹⁾

Inventory and manufacturing-related charges include excess and obsolete inventory charges on certain product lines we intend to discontinue, incremental cost of products sold from stepping up inventory to its fair value from its manufactured cost in business combination accounting and other inventory and manufacturing-related charges or gains.

⁽²⁾

We exclude intangible asset amortization from our non-GAAP financial measures because we internally assess our performance against our peers without this amortization. Due to various levels of acquisitions among our peers, intangible asset amortization can vary significantly from company to company.

⁽³⁾

In the first quarter of 2020, we recognized goodwill impairment charges of $470.0 million and $142.0 million related to our EMEA and Dental reporting units, respectively. In the second quarters of 2021 and 2020, we recognized $16.3 million and $33.0 million, respectively, of in-process research and development (“IPR&D”) intangible asset impairments on certain IPR&D projects.

⁽⁴⁾

In December 2019, our Board of Directors approved, and we initiated, a new global restructuring program that includes a reorganization of key businesses and an overall effort to reduce costs in order to accelerate decision-making and focus the organization on priorities to drive growth. Restructuring and other cost reduction initiatives also include other cost reduction initiatives that have the goal of reducing costs across the organization.

⁽⁵⁾

We are addressing inspectional observations on Form 483 and a Warning Letter issued by the U.S. Food and Drug Administration (“FDA”) following its previous inspections of our Warsaw North Campus facility, among other matters. This quality remediation has required us to devote significant financial resources and is for a discrete period of time. The majority of the expenses are related to consultants who are helping us to update previous documents and redesign certain processes.

⁽⁶⁾	The acquisition, integration, divestiture and related gains and expenses we have excluded from our non-GAAP financial measures resulted from the planned spinoff of NewCo and various acquisitions.

⁽⁷⁾

We are involved in routine patent litigation, product liability litigation, commercial litigation and other various litigation matters. We review litigation matters from both a qualitative and quantitative perspective to determine if excluding the losses or gains will provide our investors with useful incremental information. Litigation matters can vary in their characteristics, frequency and significance to our operating results. The litigation charges and gains excluded from our non-GAAP financial measures in the periods presented relate to product liability matters where we have received numerous claims on specific products, patent litigation and commercial litigation related to a common matter in multiple jurisdictions. In regards to the product liability matters, due to the complexities involved and claims filed in multiple districts, the expenses associated with these matters are significant to our operating results. Once the litigation matter has been excluded from our non-GAAP financial measures in a particular period, any additional expenses or gains from changes in estimates are also excluded, even if they are not significant, to ensure consistency in our non-GAAP financial measures from period-to-period.

⁽⁸⁾

The European Union Medical Device Regulation imposes significant additional premarket and postmarket requirements. The new regulations provided a transition period until May 2021 for currently-approved medical devices to meet the additional requirements. For certain devices, this transition period can be extended until May 2024. We are excluding from our non-GAAP financial measures the incremental costs incurred to establish initial compliance with the regulations related to our currently-approved medical devices. The incremental costs primarily include third-party consulting necessary to supplement our internal resources.

⁽⁹⁾	During the three and six-month periods ended June 30, 2021, we entered into certain agreements to gain access to or acquire third-party IPR&D projects.

⁽¹⁰⁾

We have incurred other various expenses from specific events or projects that we consider highly variable or that have a significant impact to our operating results that we have excluded from our non-GAAP measures. These include costs related to legal entity, distribution and manufacturing optimization, including contract terminations, gains and losses from changes in fair value on our equity investments, as well as, in the 2020 period, our costs of complying with a Deferred Prosecution Agreement (“DPA”) with the U.S. government related to certain Foreign Corrupt Practices Act matters involving Biomet and certain of its subsidiaries, which DPA concluded in February 2021.

⁽¹¹⁾

We recognized a tax benefit related to Switzerland’s Federal Act on Tax Reform and AHV Financing (“TRAF”) in addition to an impact from certain restructuring transactions in Switzerland. Also included are tax adjustments relating to ongoing impacts of tax only amortization resulting from TRAF as well as certain restructuring transactions in Switzerland.

⁽¹²⁾	Other certain tax adjustments relate to various discrete tax period adjustments.

⁽¹³⁾	Due to the reported net loss for this period, the effect of dilutive shares assuming net earnings is shown as an adjustment. Diluted share count used in Adjusted Diluted EPS is:

Page 21 of 27

	Three Months Ended		Six Months Ended
	June 30, 2020		June 30, 2020

Diluted shares		206.8		206.6
Dilutive shares assuming net earnings		1.0		1.4
Adjusted diluted shares		207.8		208.0

Page 22 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF NET CASH PROVIDED BY OPERATING
ACTIVITIES TO FREE CASH FLOW
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Net cash provided by (used in) operating activities	$	453.9		$	(52.8	)	$	700.4		$	398.1
Additions to instruments		(67.9	)		(73.6	)		(150.5	)		(159.3	)
Additions to other property, plant and equipment		(27.3	)		(19.0	)		(54.7	)		(59.2	)
Free cash flow	$	358.7		$	(145.4	)	$	495.2		$	179.6

Page 23 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF GROSS PROFIT & MARGIN TO ADJUSTED GROSS
PROFIT & MARGIN
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Net Sales	$	2,026.9		$	1,226.1		$	3,874.3		$	3,009.9
Cost of products sold, excluding intangible asset amortization		581.6			424.5			1,098.0			911.6
Intangible asset amortization		154.6			147.7			310.1			295.3
Gross Profit	$	1,290.7		$	653.9		$	2,466.2		$	1,803.0

Inventory and manufacturing-related charges		7.9			1.4			2.0			2.0
Restructuring and other cost reduction initiatives		0.1			-			0.2			-
Quality remediation		-			0.2			-			(0.3	)
Intangible asset amortization		154.6			147.7			310.1			295.3
Adjusted gross profit	$	1,453.3		$	803.2		$	2,778.5		$	2,100.0


Gross margin		63.7	%		53.3	%		63.6	%		59.9		%
Inventory and manufacturing-related charges		0.4			0.1			0.1			0.1
Restructuring and other cost reduction initiatives		-			-			-			-
Quality remediation		-			-			-			-
Intangible asset amortization		7.6			12.1			8.0			9.8
Adjusted gross margin		71.7	%		65.5	%		71.7	%		69.8		%

Page 24 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF OPERATING PROFIT (LOSS) & MARGIN TO ADJUSTED OPERATING PROFIT & MARGIN
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 and 2020
(in millions, unaudited)


	Three Months Ended June 30,								Six Months Ended June 30,
	2021				2020				2021				2020
Operating profit (loss)	$	220.5			$	(171.7	)		$	486.1			$	(627.7	)
Inventory and manufacturing-related charges		7.9				1.4				2.0				2.0
Intangible asset amortization		154.6				147.7				310.1				295.3
Goodwill and intangible asset impairment		16.3				33.0				16.3				645.0
Restructuring and other cost reduction initiatives		19.7				28.0				41.6				73.0
Quality remediation		11.0				9.9				21.2				25.8
Acquisition, integration, divestiture and related		25.4				2.2				38.8				6.6
Litigation		3.6				1.3				9.7				81.1
European Union Medical Device Regulation		10.6				6.1				17.5				17.1
Certain R&D agreements		65.0				-				65.0				-
Other charges		(4.5	)			11.9				(1.9	)			17.8
Adjusted operating profit	$	530.1			$	69.8			$	1,006.4			$	536.0


Operating profit (loss) margin		10.9		%		(14.0	)	%		12.6		%		(20.9	)	%
Inventory and manufacturing-related charges		0.4				0.1				0.1				0.1
Intangible asset amortization		7.6				12.1				8.0				9.8
Goodwill and intangible asset impairment		0.8				2.7				0.4				21.4
Restructuring and other cost reduction initiatives		1.0				2.3				1.1				2.4
Quality remediation		0.5				0.8				0.5				0.9
Acquisition, integration, divestiture and related		1.3				0.2				1.0				0.2
Litigation		0.2				0.1				0.2				2.7
European Union Medical Device Regulation		0.5				0.5				0.5				0.6
Certain R&D agreements		3.2				-				1.7				-
Other charges		(0.2	)			0.9				(0.1	)			0.6
Adjusted operating profit margin		26.2		%		5.7		%		26.0		%		17.8		%

Page 25 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF EFFECTIVE TAX RATE TO ADJUSTED EFFECTIVE TAX RATE
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 and 2020
(unaudited)


	Three Months Ended June 30,								Six Months Ended June 30,
	2021				2020				2021				2020
Effective tax rate		18.0		%		6.2		%		13.8		%		1.2		%
Tax effect of adjustments made to earnings before taxes⁽¹⁾		8.7				35.0				7.2				13.5
Swiss tax reform		(8.9	)			(0.3	)			(4.7	)			2.3
Other certain tax adjustments		(1.3	)			1.9				-				(0.4	)
Adjusted effective tax rate		16.5		%		42.8		%		16.3		%		16.6		%

⁽¹⁾ Includes inventory and manufacturing-related charges; intangible asset amortization; goodwill impairment; restructuring and other cost reduction initiatives; quality remediation; acquisition, integration, divestiture and related; litigation; European Union Medical Device Regulation; certain R&D agreements, and other charges

Page 26 of 27

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF DEBT TO NET DEBT
AS OF JUNE 30, 2021 and DECEMBER 31, 2020
(in millions, unaudited)


	June 30, 2021			December 31, 2020
Debt, both current and long-term	$	7,852.5		$	8,126.5
Cash and cash equivalents		(1,042.4	)		(802.1	)
Net debt	$	6,810.1		$	7,324.4

Page 27 of 27

GRAPHIC 3 gszf1kkbkpqu000001.jpg GRAPHIC begin 644 gszf1kkbkpqu000001.jpg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end EX-101.SCH 4 zbh-20210803.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 5 zbh-20210803_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 zbh-20210803_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document and entity information. Document and entity information. Document And Entity Information [Table] Document And Entity Information [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Common Stock [Member] Common Stock [Member] One point four one four percentage notes due two thousand twenty two. One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member] One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member] Two point four two five percentage notes due two thousand twenty six. Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member] Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member] One point one six four percentage notes due two thousand twenty seven member. One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member] One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Amendment Flag Amendment Flag Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 zbh-20210803_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 zbh-8k_20210803_htm.xml IDEA: XBRL DOCUMENT 0001136869 2021-08-03 2021-08-03 0001136869 us-gaap:CommonStockMember 2021-08-03 2021-08-03 0001136869 zbh:OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember 2021-08-03 2021-08-03 0001136869 zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember 2021-08-03 2021-08-03 0001136869 zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember 2021-08-03 2021-08-03 false 0001136869 8-K 2021-08-03 ZIMMER BIOMET HOLDINGS, INC. DE 001-16407 13-4151777 345 East Main Street Warsaw IN 46580 (574) 267-6131 false false false false Common Stock, $0.01 par value ZBH NYSE 1.414% Notes due 2022 ZBH 22A NYSE 2.425% Notes due 2026 1.164% Notes due 2027 ZBH 26 ZBH 27 NYSE NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2

Document and Entity Information

Aug. 03, 2021

Document And Entity Information [Line Items]

Amendment Flag false

Entity Central Index Key 0001136869

Document Type 8-K

Document Period End Date Aug. 03, 2021

Entity Registrant Name ZIMMER BIOMET HOLDINGS, INC.

Entity Incorporation State Country Code DE

Entity File Number 001-16407

Entity Tax Identification Number 13-4151777

Entity Address, Address Line One 345 East Main Street

Entity Address, City or Town Warsaw

Entity Address, State or Province IN

Entity Address, Postal Zip Code 46580

City Area Code (574)

Local Phone Number 267-6131

Written Communications false

Soliciting Material false

Pre Commencement Tender Offer false

Pre Commencement Issuer Tender Offer false

Entity Emerging Growth Company false

Common Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title Common Stock, $0.01 par value

Trading Symbol ZBH

Security Exchange Name NYSE

One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]

Document And Entity Information [Line Items]

Security 12b Title 1.414% Notes due 2022

Trading Symbol ZBH 22A

Security Exchange Name NYSE

Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]

Document And Entity Information [Line Items]

Security 12b Title 2.425% Notes due 2026

Trading Symbol ZBH 26

Security Exchange Name NYSE

One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]

Document And Entity Information [Line Items]

Security 12b Title 1.164% Notes due 2027

Trading Symbol ZBH 27

Security Exchange Name NYSE

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details

Name: dei_PreCommencementIssuerTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details

Name: dei_PreCommencementTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
+ Details

Name: dei_SolicitingMaterial

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details

Name: dei_WrittenCommunications

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Document and entity information.
+ References
No definition available.
+ Details

Name: zbh_DocumentAndEntityInformationLineItems

Namespace Prefix: zbh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=zbh_OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=zbh_TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=zbh_OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 5 96 1 false 4 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports zbh-8k_20210803.htm zbh-20210803.xsd zbh-20210803_def.xml zbh-20210803_lab.xml zbh-20210803_pre.xml zbh-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zbh-8k_20210803.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "zbh-20210803_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "zbh-8k_20210803.htm" ] }, "labelLink": { "local": [ "zbh-20210803_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "zbh-20210803_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "zbh-20210803.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 3, "memberStandard": 1, "nsprefix": "zbh", "nsuri": "http://www.zimmerbiomet.com/20210803", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "zbh-8k_20210803.htm", "contextRef": "C_0001136869_20210803_20210803", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "zbh-8k_20210803.htm", "contextRef": "C_0001136869_20210803_20210803", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.zimmerbiomet.com/20210803", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.zimmerbiomet.com/20210803", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One point four one four percentage notes due two thousand twenty two.", "label": "One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]", "terseLabel": "One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]" } } }, "localname": "OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember", "nsuri": "http://www.zimmerbiomet.com/20210803", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "zbh_OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One point one six four percentage notes due two thousand twenty seven member.", "label": "One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]", "terseLabel": "One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]" } } }, "localname": "OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember", "nsuri": "http://www.zimmerbiomet.com/20210803", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "zbh_TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two point four two five percentage notes due two thousand twenty six.", "label": "Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]", "terseLabel": "Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]" } } }, "localname": "TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember", "nsuri": "http://www.zimmerbiomet.com/20210803", "presentation": [ "http://www.zimmerbiomet.com/20210803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001564590-21-039937-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-039937-xbrl.zip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end

Document and Entity Information	Aug. 03, 2021
Document And Entity Information [Line Items]
Amendment Flag	false
Entity Central Index Key	0001136869
Document Type	8-K
Document Period End Date	Aug. 03, 2021
Entity Registrant Name	ZIMMER BIOMET HOLDINGS, INC.
Entity Incorporation State Country Code	DE
Entity File Number	001-16407
Entity Tax Identification Number	13-4151777
Entity Address, Address Line One	345 East Main Street
Entity Address, City or Town	Warsaw
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46580
City Area Code	(574)
Local Phone Number	267-6131
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Common Stock, $0.01 par value
Trading Symbol	ZBH
Security Exchange Name	NYSE
One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]
Document And Entity Information [Line Items]
Security 12b Title	1.414% Notes due 2022
Trading Symbol	ZBH 22A
Security Exchange Name	NYSE
Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]
Document And Entity Information [Line Items]
Security 12b Title	2.425% Notes due 2026
Trading Symbol	ZBH 26
Security Exchange Name	NYSE
One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]
Document And Entity Information [Line Items]
Security 12b Title	1.164% Notes due 2027
Trading Symbol	ZBH 27
Security Exchange Name	NYSE